Edition:
United Kingdom

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

1.76USD
3:53pm GMT
Change (% chg)

$0.05 (+2.92%)
Prev Close
$1.71
Open
$1.70
Day's High
$1.76
Day's Low
$1.70
Volume
14,460
Avg. Vol
147,251
52-wk High
$5.50
52-wk Low
$1.08

Latest Key Developments (Source: Significant Developments)

Catabasis Pharmaceuticals reports third quarter financial results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Catabasis Pharmaceuticals Inc :Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress.Q3 loss per share $0.31.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.Catabasis Pharmaceuticals Inc - co's current operating plan provides for cash to fund operations through august 2018​.  Full Article

James Flynn reports 4.21 pct passive stake in Catabasis Pharma - SEC filing
Friday, 30 Sep 2016 

:James Flynn reports 4.21 percent passive stake in Catabasis Pharmaceuticals Inc as of September 28 - SEC filing.  Full Article

Catabasis Pharma & Sarepta Therapeutics to collaborate in Duchenne muscular dystrophy
Thursday, 29 Sep 2016 

Catabasis Pharmaceuticals Inc : Collaboration to study exon skipping treatment by Sarepta with co's oral NF-KB inhibition treatment in mouse model of DMD . Catabasis Pharmaceuticals and Sarepta Therapeutics announce a joint research collaboration in Duchenne muscular dystrophy .Collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy.  Full Article

Catabasis announces pricing of an underwritten offering of 2.5 mln shares
Friday, 23 Sep 2016 

Catabasis Pharmaceuticals Inc [CATB.O] : Catabasis Pharmaceuticals announces pricing of $10 million offering of common stock .Catabasis Pharmaceuticals Inc says pricing of an underwritten offering of 2.5 million shares of its common stock at a price of $4.00 per share.  Full Article

Catabasis Pharmaceuticals reports Q2 loss per share $0.61
Thursday, 11 Aug 2016 

Catabasis Pharmaceuticals Inc : Catabasis Pharmaceuticals reports second quarter 2016 financial results and recent corporate highlights . Q2 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.61.  Full Article

Boston Pharmaceuticals appoints chief financial officer
Thursday, 21 Jul 2016 

Boston Pharmaceuticals : Boston Pharmaceuticals appoints Ian Sanderson as chief financial officer . Sanderson joins co from Catabasis Pharmaceuticals, where he was CFO Further company coverage: [CATB.O].  Full Article

Catabasis Pharmaceuticals board appoints Deirdre Cunnane as principal financial officer
Friday, 1 Jul 2016 

Catabasis Pharmaceuticals Inc :On June 30, board appointed Deirdre A. Cunnane, as co's principal financial officer until a CFO is named - SEC filing.  Full Article

Catabasis Pharmaceuticals files for mixed shelf of up to $100 mln - SEC Filing
Friday, 1 Jul 2016 

Catabasis Pharmaceuticals Inc :Files for mixed shelf of up to $100 mln - SEC Filing.  Full Article

Catabasis Pharmaceuticals says do not expect to invest further in CAT-2054
Tuesday, 7 Jun 2016 

Catabasis Pharmaceuticals: Announces top-line phase 2A results for CAT-2054 . Do not expect to invest further in CAT-2054 for hypercholesterolemia . All four doses of CAT-2054 in trial were generally well tolerated .Plans to submit data from the trial for presentation at an upcoming medical meeting.  Full Article

Catabasis Pharmaceuticals reports Q1 loss per share $0.61
Thursday, 12 May 2016 

Catabasis Pharmaceuticals Inc : Q1 loss per share $0.61 .Q1 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Catabasis Pharmaceuticals reports third quarter financial results

* Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress